Endoscopic ultrasound-guided intraportal injection of autologous bone marrow in patients with decompensated liver cirrhosis:A case series

BACKGROUND Recently,stem cell therapy has been extensively studied as a promising treatment for decompensated liver cirrhosis(DLC).Technological advances in endoscopic ultrasonography(EUS)have facilitated EUS-guided portal vein(PV)access,through which stem cells can be precisely infused.AIM To investigate the feasibility and safety of fresh autologous bone marrow injection into the PV under EUS guidance in patients with DLC.METHODS Five patients with DLC were enrolled in this study after they provided written informed consent.EUS-guided intraportal bone marrow injection with a 22G FNA needle was performed using a transgastric,transhepatic approach.Several parameters were assessed before and after the procedure for a follow-up period of 12 mo.RESULTS Four males and one female with a mean age of 51 years old participated in this study.All patients had hepatitis B virus-related DLC.EUS-guided intraportal bone marrow injection was performed in all patients successfully without any complications such as hemorrhage.The clinical outcomes of the patients revealed improvements in clinical symptoms,serum albumin,ascites,and Child-Pugh scores throughout the 12-mo follow-up.CONCLUSION The use of EUS-guided fine needle injection for intraportal delivery of bone marrow was feasible and safe and appeared effective in patients with DLC.This treatment may thus be a safe,effective,non-radioactive,and minimally invasive treatment for DLC.

Effect of Xuebijing injection on hematopoietic homeostasis of LPS induced sepsis in mice

Objective:To explore the effect and mechanism of Xuebijing injection (XBJ) on the hematopoietic homeostasis of bone marrow (BM) in septic mice. Methods:BM cells stimulated with XBJ were analyzed by inverted optical microscope and qPCR, to evaluate the effect of XBJ on differentiation function of BM cells in vitro. Lipopolysaccharide (LPS) 055:B5 at the dose of 20mg/kg was used to establish the sepsis model. To determine the hematopoietic stem cells homeostasis affected by LPS in mice, BM cells were isolated and analyzed by flow cytometry based on the immunophenotypic surface markers. 20ml/kg of XBJ was administered by tail vein once/day after peritoneal injection of LPS. All animals were sacrificed on the fifth day. The frequency of hematopoietic stem cells (HSC) and immune cells in mice were quantified by flow cytometry. The gene expression of transcription factors were detected by qPCR. Results:XBJ promoted myeloid differentiation of BM cells in vitro, which may be related to the mRNA expression of the transcription factors. The results in vivo showed the percentage of BM Lin-SCA-1+c-KIT+(LSK) cells, and Long-term HSCs (LT-HSC) were significantly increased in LPS group. But the percentage of multipotential progenitors (MPPs), granulocyte-monocyte progenitor (GMP) and megakaryocytic-erythroid precursor (MEP) were significantly decreased in LPS group. Whereas, XBJ improved the immune function in sepsis mice by suppression the LSK expansion in vivo. The result of qPCR showed that LSD1 and PU.1 mRNA expression in XBJ group were significantly higher than LPS group and control group respectively. Conclusion:Xuebijing injection can improve immune function in sepsis mice by regulating hematopoietic homeostasis. Its mechanism may be related to the up-regulation of LSD1 and PU.1 gene expressions.

Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations

Retinal degenerative diseases affecting the outer retina in its many forms(inherited,acquired or induced)are characterized by photoreceptor loss,and represent currently a leading cause of irreversible vision loss in the world.At present,there are very few treatments capable of preventing,recovering or reversing photoreceptor degeneration or the secondary retinal remodeling,which follows photoreceptor loss and can also cause the death of other retinal cells.Thus,these diseases are nowadays one of the greatest challenges in the field of ophthalmological research.Bone marrow derived-mononuclear stem cell transplantation has shown promising results for the treatment of photoreceptor degenerations.These cells may have the potential to slow down photoreceptor loss,and therefore should be applied in the early stages of photoreceptor degenerations.Furthermore,because of their possible paracrine effects,they may have a wide range of clinical applications,since they can potentially impact on several retinal cell types at once and photoreceptor degenerations can involve different cells and/or begin in one cell type and then affect adjacent cells.The intraocular injection of bone marrow derived-mononuclear stem cells also enhances the outcomes of other treatments aimed to protect photoreceptors.Therefore,it is likely that future investigations may combine bone marrow derived-mononuclear stem cell therapy with other systemic or intraocular treatments to obtain greater therapeutic effects in degenerative retinal diseases.

中医药联合医用水凝胶治疗疾病的策略及意义

背景:医用水凝胶是具有三维结构网络的新型功能高分子材料,具有出色的生物相容性,目前已在组织工程领域、药物载体领域有广泛研究,但基于组织工程探究医用水凝胶与中医药结合治疗疾病的研究还处于初期探索阶段。因此,通过对医用水凝胶机制作用的剖析,整合医用水凝胶与中医药在研究中联合应用的文章,进而更好地为科研工作者提供思路,对中医药与医用水凝胶联合应用具有重要意义。目的:基于组织工程研究探讨中医药联合医用水凝胶治疗疾病的策略及意义。方法:利用PubMed和中国知网数据库,检索有关中医药联合医用水凝胶在组织工程中应用的文献,检索时间为2010年1月至2022年11月,英文检索词为“hydrogel,traditional Chinese medicine,drug carrier,tissue engineering”,中文检索词为“医用水凝胶、中医药、药物载体、组织工程”。根据纳入与排除标准对所有文章进行初筛后,最终纳入61篇文章进行综述。结果与结论:①中医药联合医用水凝胶的应用虽然在关节内、组织器官内、软组织伤口和组织工程等方面有所涉及,但除了中医药结合水凝胶敷料在临床应用治疗软组织损伤外,其他方面尚处于基础实验阶段。②中医药联合医用水凝胶的发展有着巨大潜力和发展前景,但对于性能要求较高的凝胶在制造方面存在一定难度,理化性质精确掌握难度较大。③目前综合来看可注射水凝胶凭借着简便易用的特点,其在与中医药联合使用可延伸范围较广,可用于关节、器官和组织工程相关疾病的治疗;智能水凝胶有较高的灵敏度和可逆转化性也可满足特殊环境下的使用;将两者结合的中医药使用过程中还需要明确中药成分的作用机制。④中医药联合医用水凝胶治疗疾病的策略应着手于中医药对器官、组织、细胞的治疗作用联合适当种类的医用水凝胶进行匹配,可弥补传统中医给药方式和频繁给药的不足,在组织工程方面可以用水凝胶负载中药干预后的干细胞,或者同时负载中药和干细胞用于相关疾病的治疗。⑤在中医药联合医用水凝胶应用的未来研究中,还需要考虑:应当确保医用水凝胶生物性能可以量化,以不同材料不同制造工艺把握水凝胶特性,制造出所需要的符合应用条件的医用水凝胶;在中医药方面需要对已知中药单体、中药复方提取物的治疗效果和应用机制全面了解剖析,在更明了的机制下实现中医药与医用水凝胶更多更完美的结合;借助医学科技创新能力的不断提高,医用水凝胶可以创新性地结合中医药其他传统治疗方法比如针灸、推拿和拔罐等方式进行多角度运用。

Preliminary Study on the Mechanism of Acupoint Injection of Bone Marrow Mesenchymal Stem Cells in Improving Blood Flow in the Rat of Hind Limb Ischemia

Objective:To explore the mechanism of acupoint injection of bone marrow mesenchymal stem cells(BM-MSCs) in improving blood flow in the rat with hind limb ischemia.Methods:Twenty-four SD rats were randomly divided into 4 groups:normal control group(n=6),model group(n=6),BM-MSCs acupoint injection group(AI group,n=6) and BM-MSC intramuscular injection group(MI group,n=6).Sanyinjiao(SP 6),Housanli(ST 36),Zhaohai(KI 6),Huantiao(GB 30) and Yanglingquan(GB 34) were selected for the AI group,and five non-acupoints were selected on gastrocnemius and adductor of ischemic hind limbs in the MI group.BM-MSCs were injected to the latter two groups.The rat hind limb ischemia model was established with the method of blocking the femoral artery and its branches.Three weeks after injection of BM-MSCs,in each group,hindlimb adductor and gastrocnemius were taken from the ischemic side.Expressions of vascular endothelial growth factor(VEGF) and transfer growth factor-β1(TGF-β1) in the skeletal muscle were determined with immunohistochemical method,and the small arteries in the skeletal muscle were labeled with α-SMA immunohistochemical staining method,the density of small arteries(number of arterioles /number of muscle fibers) and the number of the blood vessel with VEGF positive expression were calculated.The serum levels of VEGF and nitric oxide(NO) were detected.Results:Compared with the model group,the expression of VEGF and TGF-β1,and the density of small arteries and the number of VEGF-positive blood vessels in the AI group and the MI group significantly increased(both P<0.01).Compared with the MI group,the density of small arteries and the number of VEGF-positive blood vessels in the AI group significantly increased(both P<0.01);Compared with the model group and the normal control group,the serum expression quantity of NO and VEGF in the AI group and the MI group were significantly increased(P<0.01).Conclusions:Acuppoint injection of BM-MSCs secrets more VEGF,TGF-β1 and NO to increase angiogenesis and arteriogenesis,so as to improve blood flow of the rats of hind limb ischemic.

基于CiteSpace的急危重症患者救治新体系的可视化分析

目的 基于CiteSpace了解急危重症患者救治的研究现状、研究热点和未来发展趋势。方法 检索2020至2023年CNKI数据库中的相关文献,通过CiteSpace分析急危重症患者救治的研究现状、热点及趋势。结果 研究共获得文献199篇;研究合作不密切,关键词集中于院前急救、转运和阶梯型治疗,其中院前急救和患者转运是研究前沿。结论 近年来,随着急危重症患者数量的增加,相关救治研究也呈增长趋势。未来需加强研究合作,提升研究质量,并持续推动救治体系的建立与完善,以促进急危重症救治领域的发展。

丹参注射液诱导间质干细胞分化为神经元样细胞

【目的】丹参注射液体外定向诱导成人骨髓间质干细胞 (MSC)分化为神经元样细胞。【方法】采用Ficoll Paque液离心分离成人MSC ,体外扩增 ,流式细胞仪检测MSC表面抗原表达 ,分别采用含丹参注射液或硫代甘油等试剂的无血清达乐伯克改良必需基本培养基 (DMEM )诱导MSC分化为神经元 ,免疫组化鉴定神经元特异性烯醇化酶 (NSE)、神经丝蛋白(NF M )、胶质纤维酸性蛋白 (GFAP)、巢蛋白 (nestin)的表达。【结果】成人骨髓间质干细胞在体外扩增原代可获得 0 5× 10 6,15代可获得 (2～ 3)× 10 12 个细胞 ,细胞流式细胞仪检测结果显示CD2 9、CD44、CD90、CD10 5、CD16 6表达阳性 ,CD11a、CD14、CD34、CD38、CD45、CD80、CD86为阴性。加入丹参或硫代甘油诱导后 ,MSC胞体收缩 ,突起伸出 ;免疫组化显示诱导出的神经元样细胞NSE、NF M、nestin表达阳性 ,GFAP阴性。

刺五加注射液体外诱导骨髓基质细胞分化为神经元样细胞的机制研究

目的:研究核因子-κB(NF-κB)在刺五加诱导骨髓基质细胞(MSCs)分化为神经元样细胞中的作用。方法:试验分对照组和刺五加诱导组。采用倒置显微镜观察细胞形态;免疫荧光检测MSCs表型、诱导后神经细胞标记蛋白表达和NF-κB亚基p65核移位情况;Western blot法检测诱导组、对照组IκBα的表达。结果:刺五加诱导1 h,可见部分细胞体积缩小,立体感增强,胞体收缩成锥形或球形;诱导5 h,较多细胞成三角形或球形,细胞微丝收缩,伪足形成细长突起,局部交织成网,部分细胞脱落、死亡。诱导7 d,多数细胞成锥形、三角形、球形,交织成网,形成较典型的神经元样细胞。对照组5 h时细胞无明显形态变化,7 d时偶见锥形细胞。免疫荧光检测到诱导组诱导1 h时nestin表达即为强阳性,到第7天仍为阳性,而β-ⅢTubulin在第1小时为弱阳性,3,5 h则为强阳性,并持续到7 d仍为阳性。神经细胞特异性烯醇化酶(NSE)在第3小时为弱阳性,第5,7天则为强阳性,未见胶质细胞标记蛋白GAFP的表达;对照组各标记蛋白表达均为阴性或可疑或弱阳性。对照组出现p65由胞浆向胞核移位,而诱导组p65信号主要仍在胞浆中表达。Western blot发现诱导前IκBα蛋白相对IA为1.0,诱导后刺五加组IκBα蛋白相对IA为0.455 6±0.100 8,较诱导前明显下降(P<0.01)。诱导后对照组IκBα蛋白相对IA为0.029 6±0.009 9,较诱导前及诱导组明显下降(P<0.01)。结论:刺五加可诱导MSCs分化为神经元样细胞。在此过程中,刺五加可以抑制NF-κB的活化。

经皮自体骨髓注射治疗单纯性骨囊肿疗效评价

目的评价经皮自体骨髓注射治疗单纯性骨囊肿的疗效，探讨影响疗效的相关因素。方法2000年3月～2005年6月收治单纯性骨囊肿患儿并获随访31例，男18例，女13例。年龄5岁7个月～15岁，平均9岁6个月。肱骨近端18例，股骨近端7例，肱骨干2例，腓骨近端、股骨远端、胫骨远端及跟骨各1例。活动期13例，静止期18例。其中植骨术后复发2例，类固醇注射5次未愈合1例。合并病理性骨折19例。患儿均先抽去囊液后，注入从髂后上棘吸取的骨髓，平均注入骨髓40ml（30～70m1）。结果术中及术后无并发症发生。31例获随访1～5年，平均2．2年。经1次注射后囊腔完全愈合9例，占29．0％；基本愈合7例，占22．6％；部分愈合5例，占16．1％；未愈合8例，占25．8％；无效2例，占6．5％。骨囊肿静止期与活动期疗效差异有统计学意义（P〈0．05）；5～8岁年龄段与9～15岁年龄段、骨髓增生活跃组与增生明显活跃组、肱骨近端病灶与股骨近端疗效比较，差异均无统计学意义（P〉0．05）。结论经皮注射自体骨髓治疗单纯性骨囊肿安全、有效，但1次注射疗效有限，部分需多次注射；静止期疗效优于活动期。

骨髓间充质干细胞复合纤维蛋白封闭剂体内构建可注射性组织工程软骨

目的探讨利用人骨髓间充质干细胞(marrowmesenchymalstemcells,MSCs)与可注射性纤维蛋白封闭剂(fibrinsealant,FS)复合,在裸鼠体内构建组织工程软骨的可行性。方法体外分离扩增健康人MSCs,以含有转化生长因子β1(transforminggrowthfactorβ1,TGF-β1)、地塞米松、维生素C的培养基进行成软骨诱导,诱导第7、14天分别检测软骨细胞特异的生物学特性。将诱导7d的MSCs与FS复合,接种于裸鼠背部皮下作为实验组,同时设单纯只注射FS或MSCs的支架对照组和细胞对照组。分别于接种后6、12周取材进行大体观察,行HE、阿尔新蓝染色和型胶原免疫组织化学染色评价其成软骨能力。结果MSCs以特定的培养基诱导后由纺锤形变为多角形,并表达软骨细胞分泌的基质。复合物接种6和12周后,实验组均可形成软骨样组织块,6周时形成的组织块较小而质地柔韧,陷窝清楚,可检测到阳性阿尔新蓝及型胶原表达;12周形成的组织块较大,质地较硬,表面光滑,软骨细胞位于成熟的陷窝中,阿尔新蓝及型胶原免疫组化阳性染色较6周增强。两个对照组均无软骨样组织块形成。结论MSCs复合FS可以作为一种较优良的可注射性组织工程软骨的构建方法。

参附注射液对冠心病慢性心力衰竭患者心功能及骨髓干细胞动员的影响

目的探讨参附注射液对慢性心力衰竭患者心功能及骨髓干细胞动员的影响。方法将63例冠心病慢性心力衰竭患者随机分为治疗组31例和对照组32例。对照组采用西医常规治疗,治疗组在西医常规治疗的基础上加用参附注射液40mL稀释后静脉滴注,每天1次。治疗7天后比较两组患者治疗前后心功能指标左室射血分数(left ventricular ejection fraction,LVEF)、每搏量(stroke volume,SV)、心输出量(cardiac output,CO)及外周血CD3+4细胞数量的变化。结果两组治疗后心功能指标LVEF、SV、CO均较治疗前有改善(P<0.01),组间比较治疗组改善的程度优于对照组(P<0.05);对照组治疗后外周血CD3+4细胞数量无明显变化,治疗组治疗后外周血CD3+4细胞数量较治疗前明显升高,差异有统计学意义(P<0.01)。结论参附注射液能明显改善心脏收缩功能,且能显著增加外周血CD3+4细胞数量,促进骨髓干细胞动员,这可能是其改善心功能的机制之一。

浓缩自体骨髓移植结合金葡液局部注射对骨质疏松性骨折愈合过程中BMP-2和VEGF表达的调控

[目的]探讨浓缩自体骨髓移植结合金葡液注射治疗骨质疏松性骨折的疗效及其可能的分子机理。[方法]5月龄雌性家兔80只，体重2.5-3.0kg，采用去势法建造OPF动物模型，随机分成4组。分别为浓缩自体骨髓移植结合金葡液局部注射治疗组（A组）、浓缩自体骨髓移植治疗组（B组）、金葡液局部注射治疗组（C组）、未治疗组（D组），每组20只。分四个时间点（2W、4W、6W、8W）处死动物取材，进行X线摄片、测定骨痂CT值、BMP-2及VEGF染色阳性细胞计数观察。[结果]各取材时间A组X线表现明显优于其它三组，A组第8W时骨折线基本消失。CT值对比显示各组CT值呈递增趋势，A组递增幅度最大，D组递增幅度最小，同一时间点取材各组骨痂CT值比较发现A组骨痂CT值均高于其它组（P〈0.01）。HE染色显示A组在2、4W时软骨细胞、成骨细胞较多，6、8W取材时可见细胞都已经成熟；D组第8W时仍较多软骨细胞存在。免疫组化结果显示2W时A组骨痂细胞中BMP-2、VEGF的表达量均高于其它组；第8W时A、B、C组表达量均极少，D组表达量高于前3组。[结论]浓缩自体骨髓移植结合金葡液局部注射能促进骨质疏松性骨折愈合，其作用明显优于单纯应用骨髓移植治疗或单纯金葡液局部注射治疗，其机理可能是提高了骨折早中期BMP-2和VEGF的表达。

Shenfu injection protects against myelosuppression from chemotherapy

Cyclophosphamide is used to treat a variety of tumors. However, the success of the treatment is limited due to severe myelosuppression caused by cyclophosphamide. Administration of cyclophosphamide could significantly decrease white blood cells （WBCs）, platelets, red blood cells （RBCs）, as well as hemoglobin level. The aim of this research is to investigate the protective role of Shenfu injection against cyclophosphamide induced myelosuppression. The results showed that Shenfu injection can markedly enhance the level of WBCs, platelets, RBCs, and hemoglobin of myelosuppressed rat. The level of WBCs, platelets, RBCs, and hemoglobin were increased by 70%-100%, 80%-90%, 10%-20% and 10%-20%, respectively. Furthermore, the protective role of Shenfu injection against myelosuppression was confirmed by the microscopic observation of bone marrow sections. In conclusion, Shenfu injection has a potential protective effect against cyclophosphamide-induced myelotoxicity.

香丹注射液定向诱导大鼠骨髓间质干细胞分化为神经元的特点及其影响因素

目的探讨香丹注射液诱导成年SD大鼠骨髓间质干细胞 (rMSCs)定向分化为神经元样细胞的特点和影响因素。方法体外培养rMSCs至第 5代 ,培养基中加入碱性成纤维生长因子 (bFGF)预诱导2 4h ,更换含不同浓度香丹注射液的诱导液诱导 ,比较香丹注射液rMSCs分化 (诱导率 )在不同的培养基组成、诱导剂浓度和接种时的细胞密度等因素的影响 ,并用台盼蓝染色法、四唑盐比色法 (MTT法 )评判上述因素对诱导后细胞存活率的影响。结果 1%～ 5 %香丹注射液的诱导组 ,均可诱导rMSCs分化为神经元样细胞 ,诱导后 6～ 12h诱导率可达 (83 5± 3 8) % ,90 %以上的细胞存活时间 >36h。其他条件相同时 ,香丹注射液 3%～ 5 %的浓度组、无血清的D/F12 +N2 +bFGF诱导组和 2 5× 10 4 /cm2 的细胞接种密度 ,可得到最高的诱导率和细胞存活率。结论 3%～ 5 %的浓度、无血清D/F12 +N2 +bFGF(10 μg/L)和 2 5× 10 4 /cm2 的细胞接种密度是香丹注射液定向诱导rMSCs分化为神经元样细胞的最适条件。

康莱特注射液联合化疗对晚期肺癌患者癌痛症状、免疫功能及短期疗效的影响

目的探讨康莱特注射液联合化疗对晚期肺癌患者癌痛症状、免疫功能及短期疗效的影响。方法选取2015年1月—2019年2月收治的晚期非鳞状细胞非小细胞肺癌患者62例,根据患者采取的不同治疗方案分组,27例患者接受AP化疗方案(培美曲塞^+卡铂)纳入对照组,35例患者接受康莱特注射液联合AP化疗方案纳入观察组,21 d为1个疗程,共2个疗程。化疗2个疗程后评价短期疗效、癌痛评分、免疫功能,并随访记录生存时间。结果观察组总有效率[45.71%(16/35)]与对照组[33.33%(9/27)]比较差异无统计学意义(P>0.05)。观察组控制率[77.14%(27/35)]与对照组控制率[59.26%(16/27)]比较差异无统计学意义(P>0.05)。第1疗程末、第2疗程末,观察组的癌痛评分均低于对照组(P<0.05);观察组的CD3^+、CD4^+水平高于对照组,CD8^+水平低于对照组(P<0.05)。观察组骨髓抑制Ⅰ~Ⅱ级不良反应发生率[40.00%(14/35)]低于对照组[70.37%(19/27)](P<0.05);观察组胃肠道反应发生率[48.57%(17/35)]低于对照组[74.07%(20/27)](P<0.05)。随访至2020年1月,观察组中位生存期12.5(7.6~23.3)个月,对照组中位生存期10.2(4.5~20.0)个月,观察组生存时间大于对照组(P<0.05)。结论晚期肺癌患者化疗基础上联合使用康莱特注射液能缓解癌痛症状,改善免疫功能,减轻骨髓抑制不良反应,提高短期疗效,延长生存期,增加临床获益。

刺五加对放射损伤骨髓微血管的保护作用

目的 观察刺五加注射液对放射损伤小鼠骨髓微血管的保护作用。方法 用60 Coγ射线辐射小鼠建立骨髓微血管放射损伤模型 ;6周龄雌性小鼠随机分为正常、模型、模型 +刺五加注射液低剂量 ,模型 +刺五加注射液高剂量和模型 +复方丹参注射液 5组。采用分光光度法分别测定各组小鼠股骨骨髓血红蛋白溶液标本的吸光度 (A)值 ;鼠尾采血测定外周血红细胞、白细胞数量和血红蛋白含量 ;并分别观测骨髓毛细动脉根数、面积和骨髓造血组织容量百分率。结果 刺五加注射液能明显降低放射损伤小鼠骨髓血红蛋白含量 ,提高外周血红细胞和白细胞的数量以及增加骨髓毛细动脉根数、面积和骨髓造血组织容量百分率。结论 刺五加注射液能明显修复放射损伤小鼠骨髓微血管 。

经不同方式移植骨髓间充质干细胞治疗肝纤维化的疗效

目的:探索经不同方式移植骨髓间充质干细胞(bone marrow stem cell,BMSC)治疗肝纤维化的疗效。方法:P4代骨髓间充质干细胞经培养并诱使其向肝细胞样细胞分化;通过CCL4制作大鼠肝纤维化模型。骨髓间充质干细胞通过静脉内、肝内、及腹腔注射等移植方式。通过组织学染色,免疫组织化学和生化分析比较不同移植方式对肝脏形态及功能的影响。结果:MSCs经诱导后不表达肝细胞标记物,而表达α-胎蛋白(AFP),白蛋白(ALB);组织学染色,免疫组化,及生化分析表明经静脉途径比其他途径更有利于挽救肝衰竭。结论:MSCs移植能抵抗肝脏纤维化,静脉移植方式是最有效的治疗途径。

以藻酸钙为载体的可注射性组织工程软骨和骨研究

目的在裸鼠背部皮下注射软骨细胞/藻酸钙复合物、骨髓基质成骨细胞/藻酸钙复合物,观察体内软骨、骨形成的可行性。方法分别从兔耳软骨和髂骨获取软骨细胞和骨髓基质干细胞,体外扩增培养,将获得的软骨细胞和骨髓基质成骨细胞与藻酸盐复合,注射于裸鼠背部皮下,以单纯藻酸钙植入作为对照组,6,12周后进行组织学检查和X线检查,观察软骨和骨的形成。结果注射软骨细胞复合物组,裸鼠背部皮下有软骨样组织形成,软骨细胞位于类似于正常软骨组织的陷窝中,注射骨髓基质成骨细胞复合物组,裸鼠背部皮下有骨样组织形成,具有骨髓腔样结构,而对照组无软骨或骨形成。结论藻酸钙可用作软骨和骨组织工程的支架材料,以藻酸钙为载体的可注射性组织工程软骨和骨是可行的。

外源性BMMSCs通过改善内源性BMMSCs成骨分化能力缓解去卵巢大鼠骨质疏松

目的观察系统注射骨髓间充质干细胞(BMMSCs)是否通过改善内源性BMMSCs成骨分化能力缓解去卵巢大鼠骨质疏松。方法 12只雌性SD大鼠随机分为假手术(sham)组、去卵巢(OVX)组、高剂量(high-dose)组和低剂量(low-dose)组。建立OVX和sham模型。术后24 h,高、低剂量组分别经尾静脉注射1.5×107和0.375×107cells/kg细胞。microCT扫描股骨近端。ALP和茜素红染色检测BMMSCs成骨能力,RT-PCR检测成骨相关基因。结果 1)OVX组的骨密度(BMD)和骨小梁数量(Tb.N)低于sham组(P<0.05),OVX组内源性BMMSCs的成骨能力弱于sham组(P<0.05)。2)高剂量组的BMD和Tb.N高于OVX组(P<0.05)。高、低剂量组内源性BMMSCs的成骨能力均强于OVX组(P<0.05),高剂量组强于低剂量组(P<0.05)。结论系统注射BMMSCs通过改善OVX大鼠内源性BMMSCs的成骨分化能力,缓解OVX大鼠骨质疏松。

黄芪注射液对小鼠骨髓细胞增殖周期的影响

采用骨髓细胞体外培养以及流式细胞仪等实验血液学方法,研究黄芪注射液(AMI)对正常和贫血小鼠骨髓细胞增殖周期的影响,终浓度为 40 μg/ml的 AMI以及终浓度为40 μg/ml、400μg/ml的AMI加入培养体系中可分别促进正常或贫血小鼠骨髓细胞进入增殖活跃期(P<o.05),提示一定浓度的AMI可以增强小鼠的造血功能。